医学
内科学
肺癌
荟萃分析
肿瘤科
化疗
毒性
佐剂
药方
癌症
辅助治疗
药理学
作者
Hangxing Huang,Beicheng Liu,Mengzhen Chen,Yanfang Qin,Jianyu Li,Simin Li,Xue Xu
标识
DOI:10.1016/j.jep.2023.117665
摘要
The treatment and prognosis of patients with non-small cell lung cancer (NSCLC) was affected by the occurrence of cancer therapy-related cardiovascular toxicity (CTR-CVT). Yiqi Buxue prescriptions were a class of traditional single or compounded formulations that have become a consensus for NSCLC. There was no clear information and or summary available for Yiqi Buxue prescriptions combined with adjuvant chemotherapy for NSCLC in reducing CTR-CVT.
科研通智能强力驱动
Strongly Powered by AbleSci AI